NMDA-ANTAGONIST-PRODRUGS

European patent · EP3066091 · In force

Register entry

Publication number: EP3066091
Application number: EP14802476
Kind: European patent with effect for Switzerland and Liechtenstein
Status: In force
Specification: Granted
Filed: Oct 30, 2014
Published: Sep 14, 2016
Granted: Apr 3, 2019
Protection ends at the latest: Oct 29, 2034
Next annual fee due: Oct 31, 2026
IPC classes: C07D 401/14 (2006.01)
C07D 401/12 (2006.01)
C07D 213/40 (2006.01)
A61K 31/4402 (2006.01)
A61K 31/4439 (2006.01)
A61P 25/24 (2006.01)
Priority: US 201361899903 P 05.11.2013
PCT application: PCT/GB2014/053236 30.10.2014
PCT publication: WO2015/067923 14.05.2015
Filing language: English
Source: Swissreg

What the Federal Institute of Intellectual Property published about this title, newest first.

Nov 1, 2025
Change
Published in Swissreg on 01.11.2025
Nov 1, 2024
Change
Published in Swissreg on 01.11.2024
Jan 26, 2024
Change
Published in Swissreg on 26.01.2024
Jan 9, 2023
Address changed
Representative
ServoPatent GmbH, Wannerstrasse 9/1, 8045 Zürich → Servopatent GmbH, Bühlstrasse 1, 8125 Zollikerberg
Published in Swissreg on 09.01.2023
Nov 1, 2022
Change
Published in Swissreg on 01.11.2022
Jun 4, 2020
Address changed
Representative
Servopatent GmbH, Resirain 1, 8125 Zollikerberg → ServoPatent GmbH, Wannerstrasse 9/1, 8045 Zürich
Published in Swissreg on 04.06.2020
Jul 4, 2019
Agent entered
Representative
Servopatent GmbH, Resirain 1, 8125 Zollikerberg
Published in Swissreg on 04.07.2019
Apr 3, 2019
Granted
Published in Swissreg on 03.04.2019

Astrazeneca AB

151 85 Södertälje, SE

Bühlstrasse 1, 8125 Zollikerberg

BALESTRA, Michael

Waltham Massachusetts 02451, US

QUIRK, Michael

Waltham Massachusetts 02451, US

BERNSTEIN, Peter

Waltham Massachusetts 02451, US

WEIGELT, Dirk